PB2144: TRIAL IN PROGRESS: A PHASE 1/2 WINDOW OF OPPORTUNITY STUDY OF THE BCMAXCD3 BISPECIFIC ANTIBODY LINVOSELTAMAB IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA
Christopher J. Ferreri,
Steven Quatela,
Oluwaseun Aina,
Pourab Roy,
Anita Boyapati,
Karen Rodriguez Lorenc,
Glenn Kroog,
Robert Z Orlowski
Affiliations
Christopher J. Ferreri
1 The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Steven Quatela
2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Oluwaseun Aina
2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Pourab Roy
2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Anita Boyapati
2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Karen Rodriguez Lorenc
2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Glenn Kroog
2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Robert Z Orlowski
1 The University of Texas MD Anderson Cancer Center, Houston, TX, United States
